Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower in Wednesday's after-hours session after the company announced a proposed offering of its common stock.
What Happened: After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an underwritten public offering. All of the shares are being offered by Recursion.
The clinical-stage biotech company also said it plans to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares being offered.
Recursion had $296.3 million in cash and cash equivalents as of March 31.
The proposed offering comes just days after Recursion held its annual investor day in which NVIDIA Corp (NASDAQ:NVDA) CEO Jensen Huang made an appearance to discuss the role AI will play in drug discovery and development in the future.
Recursion has built one of the most powerful supercomputers in the biotech space with the help of Nvidia. The two companies announced a multi-year collaboration last year.
Nvidia also reported investments in multiple companies, including Recursion, in a 13-F filing with the SEC earlier this year, which garnered investor attention and sparked a short-lived surge in Recursion stock.
According to the filing, Recursion is Nvidia's second-largest investment after Arm Holdings.
Recursion Pharmaceuticals Inc(納斯達克:RXRX)的股票在週三的盤後交易中下跌,該公司宣佈擬發行其普通股的公開發行,募集資金規模爲2億美元。
事件經過:週三收盤後,Recursion 表示其打算通過承銷公開發行發行和銷售價值2億美元的普通股。所有股票均由Recursion提供。
這家臨床階段的生物技術公司還表示,計劃授權承銷商購買所發售股票的15%的期權,期限爲30天。
截至3月31日,Recursion持有現金及現金等價物2.963億美元。
該擬議發行計劃在Recursion舉辦其年度投資者日幾天後出爐,英偉達公司(納斯達克:NVDA)首席執行官黃仁勳在會上出席,討論人工智能在未來藥物發現和開發中的角色。
Recursion與英偉達的合作,使之成爲生物技術領域內最強大的超級計算機之一。兩家公司去年宣佈了一項爲期多年的合作。
此外,英偉達在今年早些時候提交給美國證券交易委員會的13F申報中也披露多個公司的投資,其中包括Recursion,引起了投資者的關注並導致Recursion 股票短暫上漲。
根據申報,Recursion是英偉達收購 Arm Holdings 後的第二大投資。